<source id="3oodw" ><sup id="3oodw" ></sup></source>

      1. <s id="3oodw" ><th id="3oodw" ><small id="3oodw" ></small></th></s>
        <i id="3oodw" ><optgroup id="3oodw" ></optgroup></i>

            <input id="3oodw" ><bdo id="3oodw" ><cite id="3oodw" ></cite></bdo></input>
            <delect id="3oodw" ><ruby id="3oodw" ></ruby></delect>

            <em id="3oodw" ><progress id="3oodw" ></progress></em><input id="3oodw" ></input>
            <strike id="3oodw" ></strike>
            India

            Multiple Dosage Forms

            Advantage for Coating Mini-Tablets in a Pan

            | Editor: Anke Geipel-Kern

            Versatility and high performance are the hallmarks of Cyclops the IMA Active's bin tumblers.
            Gallery: 2 Pictures
            Versatility and high performance are the hallmarks of Cyclops the IMA Active's bin tumblers. (Source: IMA)

            The coating of directly compressed mini-tablets in a pan has not been extensively utilised; however this process shows advantages over the fluid bed. The following study investigates the possibility of manufacturing a sustained release multiple dosage form by coating in a solid wall pan mini-tablets produced by direct compression.

            The production of mini-tablets for the sustained release of a drug is a promising area in pharmaceutical research. Mini-tablets are multiple unit dosage forms, therefore they present all the advantages of these systems over the single unit dosage forms such as low risk of dose dumping, high degree of dispersion in the GI tract and reproducible bioavailability.

            Moreover, if they are manufactured by direct compression instead of granulation or extrusion and spheronization, the production is one step and leads to lower costs and higher production yields [1, 2]. Sustained release mini-tablets can be produced either as matrix or by coating the mini-tablets in a fluid bed apparatus [3].

            Until now the coating of mini-tablets in a pan has not been extensively utilised [4]; however this process shows advantages over the fluid bed providing higher production capabilities, lower waste of coating materials and faster equipment cleaning time.

            Aim of the Study

            The aim of this research was to investigate the possibility of manufacturing a sustained release multiple dosage form by coating in a solid wall pan mini-tablets produced by direct compression; theophylline was employed as a model drug and WAS, an innovative ready to use pigment dispersion, was tested to evaluate the possibility of reducing production time.

            Experimental Part: Material

            The rawmaterial Theophylline (TH, particle lower than 100 microns) was purchased from BASF, Ludwigshafen, Germany. Avicel PH 102 was kindly supplied by FMC Biopolymer Brussels, Belgium. Spray dried lactose, magnesium stearate, talc, titanium dioxide, trietilcitrate and Yellow Quinoline (all FU grade) were purchased from Polichimica, Bologna Italy and used as received. Eudragit RL, Eudragit RS (polymer conforms to ‘Ammonio Methacrylate Copolymer, Type A’ USP/NF 31) and WAS (containing talc, Titanium dioxide, Yellow Quinoline and Trietilcitrate) were kindly supplied by Rofarma Italia, Milano Italy.

            Methods: Preparation of mini-tablets

            TH, Avicel PH 102, lactose spray dried and magnesium stearate (total 4 kg per batch) were blended using an IMA Cyclops blender. Direct compression was performed using a tablet press machine for R&D and small batches, IMA Prexima 80 , equipped with 2 EU-D punches fitting 24 mini-punches, 2 mm diameter each. Compression force used to obtain 9 mg mini-tablets was maintained at 20 kN for all batches with die feeder speed adjusted to 25 rpm.

            Coating of mini-tablets

            Coating process of 10 kg mini-tablets for each batch was performed in an IMA GS 25 L solid wall pan.

            Two different coating formulae were used (Table 1): a traditional one containing single components to be previously dispersed in water (A) and the ready to use pigment dispersion WAS (B). Both formulae were tested at different polymer amounts expressed in total solids weight gain percentage. Process parameters for formula A and B are described in Table 2.

            Characterisation

            The mini-tablets (mT) were tested for uniformity of mass, friability and crushing strength and the surface characteristics were observed by Scanning Electron Microscopy (SEM ESEM-FEI Quanta 200). The coated mini-tablets (CmT) were characterized with regards to the actual drug content and in vitro drug release profiles (USP paddle method, 50 rpm, 900 ml pH 7.4 phosphate buffer at 37 °C). The analysis was performed spectrophotometrically (UV2, Unicam) at 271.8 nm.

            Results and Discussion

            In the first part of the study, four batches of mini-tablets containing different amounts of the drug (Table 3) were producted to select the formulation which had satisfactory mechanical properties to enable their coating in a pan, minimal weight variation and maximum drug content.

            All the mini-tablets produced had suitable technological properties for the coating (high crushing strength and very low friability) and complied with the test for uniformity of mass, according to European Pharmacopoeia. Batch mT4 was then selected for coating due to the highest drug content.

            The second part of the study aimed to demonstrate the feasibility of mini-tablet coating in a solid wall pan and to test the possibility of replacing a standard coating preparation with a ready to use system. Comparing the operative parameters used in coating involving formula A and B (Table 2) it is evident that the coating conditions were very similar, this demonstrates the interchangeability of the traditional formula containing the single components with the ready to use pigment dispersion.

            SEM of uncoated mT 4, formula A at different coating levels, formula B at different coating levels
            SEM of uncoated mT 4, formula A at different coating levels, formula B at different coating levels (Source: IMA)

            The SEM photographs of uncoated mT4 and coated m-T at different level show that a complete and uniform layer was achieved using both formulae even at low coating level. As shown in Figure 4, the uncoated mT released the 100 % of active ingredients in less than 90 minutes. A sustained release was ensured by both formulae and all polymer amounts, proportionally to the coating level. At the same coating level the dissolution profiles of both formulae were not significantly different, suggesting that the ready to use system is equivalent to the traditional one.

            Conclusions

            The results obtained showed that mini-tablets having a high amount of TH, low friability and high crushing strength were obtained by direct compression. A solid wall pan represents a suitable technique for mini-tablets coating and the use of a ready to mix pigment dispersion represents a suitable method to shorten coating suspension preparation time. Therefore a sustained release multiple dosage form was successfully manufactured by using a tablet press and a solid wall pan.

            References

            [1] C. M. Lopes, J.M. Sousa Lobo, P. Costa, J.F. Pinto. 2006. Directly compressed mini matrix tablets containing ibuprofen: preparation and evaluation of sustained release. Drug. Dev. Ind. Pharm.(32) 95-106.

            [2] T. Riis, A. Bauer-Brandl, T. Wagner, H. Kranz. 2007. pH-independent drug release of an extremely poorly soluble weakly acidic drug from muliparticulated extended release formulations. Eur. J. Pharm. Biopharm. (65) 78-84.

            [3] I.Tomuta and S.E. Leucuta. 2007. The influence of formulation factors on the kinetic release of metoprolol tartrate from prolong release coated mini tablets. Drug. Dev. Ind. Pharm.(33) 1070-1077.

            [4] A. Spadoni, C. Funaro, A. Genovesi and C. Vecchio. 2001. Evaluation of an alternative dosage form to enteric coated pellets containing Ibuprofen: a case of study. Pharmaceutical Processing, 52-54.

            Comments are being loaded ....

            Leave a comment

            The comment is checked by an editor and will be released soon.

            1. Avatar
              Avatar
              Edited by at
              Edited by at
              1. Avatar
                Avatar
                Edited by at
                Edited by at

            Comments are being loaded ....

            Report comment

            Kommentar Freigeben

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            Freigabe entfernen

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            copyright

            This article is protected by copyright. You want to use it for your own purpose? Contact us via: (ID: 46351877 / Pharma & Food)